Ferulic acid supplements abrogate oxidative impairments in liver and testis in the streptozotocin-diabetic rat.
The primary objective of this study was to assess the efficacy of ferulic acid (FA), a phenolic antioxidant, in ameliorating oxidative stress in the testis and liver of diabetic pubertal rats. Male (6 wk old) rats were rendered diabetic by an acute dose (60 mg/kg body weight, intraperitoneal) of streptozotocin (STZ) and were given oral supplementation of FA (50 mg/kg body weight/d on alternate days) for 4 weeks. The protective efficacy of FA was assessed by measuring markers of oxidative stress in the testis and liver along with the effect of stress on lipid profile in serum/testis. Terminally, the testis (cytosol and mitochondria) of STZ-administered rats exhibited a marked elevation in the status of lipid peroxidation and enhanced reactive oxygen species (ROS) production compared to the non-diabetic controls. FA treatment completely normalized the oxidative impairments in the testis. Further, STZ-induced depletion of reduced glutathione (GSH) and elevated protein carbonyl content in the testis were restored to normalcy by FA treatment. The protective effects of FA were also discernible in the testis in terms of restoration of activities of various antioxidant enzymes in the diabetic rats. Furthermore, STZ-induced oxidative impairments in the liver were also abrogated significantly by FA treatment. STZ-induced perturbations in serum and testicular lipid profiles in the diabetic rats were also significantly attenuated by FA treatment. Collectively, these results indicate that oral supplementation of FA can significantly mitigate diabetes-associated oxidative impairments in the testis as well as in the liver and suggests the efficacy of FA as a complementary therapeutic agent in the management of diabetes-associated oxidative stress-mediated complications.
Thyagaraju
Badanavalu Madaiah
BM
Department of Biochemistry, Central Food Technological Research Institute, Mysore, India.
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003373:Coumaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D007274:Injections, Intraperitoneal; D015227:Lipid Peroxidation; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D013737:Testis / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D000975:Antioxidants; D003373:Coumaric Acids; D017382:Reactive Oxygen Species; C004999:ferulic acid; D005979:Glutathione Peroxidase; D005982:Glutathione Transferase